Dr. Lihui Wang
Molecular Lead
HODS, Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories.
Dr. Lihui Wang joined the Department of Haematology, Royal Liverpool University Hospital in 2000. She has been involved in establishing and standardising BCR-ABL1 gene transcript monitoring in Liverpool, UK and across the world (WHO standard). Since 2019, Dr. Wang has been the Lead Scientist for NHS England Northwest Liverpool LCL Genomic Laboratory Hub (GLH). Her role has been to establish and supervise the Haemato-oncology molecular diagnostic service for the region of Merseyside and Cheshire.
Together, Drs. Menon and Wang, and working in partnership with industry, are driving forward cutting-edge innovations in NGS, that have a national and international impact.
Dr. Geetha Menon
Clinical Director
HODS, Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories.
Dr. Menon currently leads the Haemato-oncology Diagnostic Service (HODS ) for the Cheshire & Merseyside Cancer Network. She has been instrumental in developing the vision and plan to create this unique integrated service, which combines data from immunophenotyping, morphology and molecular genetics including next generation sequencing (NGS) to derive a single diagnosis. This is one of very few services in the UK and one of only a handful that is fully integrated and currently serves the entire Cheshire & Merseyside Cancer Network.
Click the button below to speak with a Thermo Fisher Scientific representative.
